Elusive protein protects malaria parasite from heme

Researchers at the Virginia Bioinformatics Institute (VBI) at Virginia Tech have identified Heme Detoxification Protein (HDP), a unique protein encoded in the malaria genome that represents a potential target for developing new malaria drugs.

The team, which includes researchers at Washington University School of Medicine, the United States National Institutes of Health, the United States Food and Drug Administration as well as other researchers at Virginia Tech, has characterized HDP and demonstrated that it plays a major role in protecting Plasmodium as the pathogen pursues infection of its host. The findings were published April 25th in the open-access journal PLoS Pathogens.

Worldwide, the annual death toll of malaria exceeds 1 million, and children under the age of five are its major victims. The Plasmodium parasite that causes malaria in humans is transmitted through the bites of infected mosquitoes. Once inside the human body, the parasite initially develops in the liver and subsequently, upon release, infects red blood cells. After infecting host red blood cells, a rapid growth ensues, supported by the parasite’s consumption of hemoglobin, the oxygen-transporting protein that constitutes a massive 90% of the total protein present inside each red blood cell. Destruction on this scale releases large quantities of heme, the prosthetic group responsible for oxygen transport in hemoglobin. Free heme is extremely damaging and to protect itself from this toxic onslaught, the parasite utilizes a novel mechanism where it rapidly converts heme into a crystalline material known as hemozoin.

Dr. Dharmendar Rathore, Assistant Professor at VBI, remarked: “We discovered HDP as part of a functional genomics initiative that is focused on the identification of malaria proteins involved in disease pathology. A combination of cellular and biochemical approaches allowed us to rigorously characterize HDP. It appears that HDP has a number of striking features that make it a promising candidate as a drug target. HDP is not only capable of rapidly converting heme into its non-toxic counterpart hemozoin, but it is highly conserved in all the species of the parasite and also appears to be critical for its survival.” He added: “The beauty of this discovery is that, while HDP has robust interactions with heme, it lacks homology to any of the known heme-binding proteins and has therefore eluded detection during previous attempts by several groups to identify parasite factors responsible for hemozoin formation.”

The conversion of heme into hemozoin is regarded as one of the weakest links in the lifecycle of the Plasmodium parasite. For example, chloroquine, the most widely used malaria drug, works by interacting with heme and preventing its detoxification into hemozoin. However drugs are not yet available that target any of the parasite-specific molecules involved in this process.

Dr. Rana Nagarkatti, research scientist at VBI, commented: “The identification of new drug targets is an essential step in the development of next-generation drugs for treating malaria. Drugs that specifically interact with HDP and inhibit its detoxification activities could potentially have drastic effects on the viability of the malaria parasite.” Dr. Dewal Jani, a member of the VBI research team, remarked: “The identification of HDP fills an important gap in our understanding of the mechanism of hemozoin production in the malaria parasite. We have also established the route by which the HDP is transported out of Plasmodium and into the red blood cell before it subsequently returns to the parasite food vacuole where hemozoin is synthesized. This gives us an interesting insight into the inner workings of the parasite.”

Dr. Rathore concluded: “New drugs are urgently needed to address the huge public health burden posed by malaria across the globe. We have recently undertaken a high-throughput screening of chemical libraries to identify compounds that can inhibit the activity of HDP. Several lead compounds were identified and have been characterized in our laboratory at VBI and subsequently validated at the Swiss Tropical Institute in Basel, Switzerland. We see considerable potential in developing these lead compounds into new drugs that can act by blocking the function of HDP in the parasite.”

Otto Folkerts, Associate Director of Technology Development at VBI, added: “Virginia Tech Intellectual Properties Inc. has filed patents that cover the intellectual property behind this discovery. We are actively seeking partners who are interested in licensing this intellectual property or jointly pursuing the development of potential malaria drug candidates that may arise from this work.”

Source: Virginia Tech

Related stories:

Elusive protein protects malaria parasite from heme
Researchers at the Virginia Bioinformatics Institute at Virginia Tech have identified Heme Detoxification Protein, a unique protein encoded in the malaria genome that represents a potential target for developing new malaria drugs.
Genome sequences of 2 malaria parasites defined
Professor Alan Cowman, Professor Brendan Crabb, Dr Paul Gilson and Dr Toby Sargeant are WEHI members of international research teams that have made significant discoveries about two deadly malaria parasites, Plasmodium knowlesi and Plasmodium vivax.
New way to make malaria medicine also first step in finding new antibiotics
University of Illinois microbiology professor William Metcalf and his collaborators have developed a way to mass-produce an antimalarial compound, potentially making the treatment of malaria less expensive.
Purifying parasites with light
Researchers have developed a clever method to purify parasitic organisms from their host cells, which will allow for more detailed proteomic studies and a deeper insight into the biology of organisms that cause millions of cases of disease each year.
'Dodgy dossier' partly to blame for failure of war against malaria in the tropics
The war against malaria in tropical countries was fought and lost in the 20th Century on the basis of faulty intelligence, a 'dodgy dossier' which argued that the same methods used to tackle the disease in temperate countries would also work in the tropics.
Best way to treat malaria: Avoid using same drug for everyone, scientists say
(PhysOrg.com) -- A team of scientists employing a sophisticated computer model pioneered at Princeton University and Resources for the Future has found that many governments worldwide are recommending the wrong kind of malaria treatment.
A sharper look at malaria
(PhysOrg.com) -- In work that could lead to new ways of detecting and treating malaria, MIT researchers have used two advanced microscopy techniques to show in unprecedented detail how the malaria parasite attacks red blood cells.
Malaria researchers identify new mosquito virus
Researchers at the Johns Hopkins Bloomberg School of Public Health's Malaria Research Institute have identified a previously unknown virus that is infectious to Anopheles gambiae—the mosquito primarily responsible for transmitting malaria. According to the researchers, the discovered virus could one day be used to pass on new genetic information to An. gambiae mosquitoes as part of a strategy to control malaria, which kills over one million people worldwide each year. The study was published August 22 online in the peer-reviewed open access journal PLoS Pathogens.

News discussion:

General Science news